Talphera Inc. (TLPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Talphera Inc. (TLPH) has a cash flow conversion efficiency ratio of -0.272x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.92 Million) by net assets ($14.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TLPH stock market capitalisation for the company's overall valuation and market capitalisation.
Talphera Inc. - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Talphera Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Talphera Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Talphera Inc. ranked by their cash flow conversion efficiency. Explore cash flow quality index of Talphera Inc. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mink Therapeutics Inc
NASDAQ:INKT
|
148.472x |
|
Sunsuria Bhd
KLSE:3743
|
-0.024x |
|
Bonus Biogroup
TA:BONS
|
0.710x |
|
EasyJet PLC
LSE:EZJ
|
0.153x |
|
Jade Gas Holdings Ltd
AU:JGH
|
-0.048x |
|
Isbir Sentetik Dokuma Sanayi AS
IS:ISSEN
|
-0.037x |
|
HSS Engineers Bhd
KLSE:0185
|
-0.057x |
|
Noble Development Public Company Limited
BK:NOBLE
|
0.074x |
Annual Cash Flow Conversion Efficiency for Talphera Inc. (2008–2025)
The table below shows the annual cash flow conversion efficiency of Talphera Inc. from 2008 to 2025. View TLPH stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.04 Million | $-11.36 Million | -0.667x | +57.92% |
| 2024-12-31 | $8.00 Million | $-12.68 Million | -1.585x | -27.82% |
| 2023-12-31 | $14.11 Million | $-17.49 Million | -1.240x | +4.51% |
| 2022-12-31 | $21.81 Million | $-28.33 Million | -1.299x | -255.38% |
| 2021-12-31 | $-35.89 Million | $-30.00 Million | 0.836x | +21.02% |
| 2020-12-31 | $-55.75 Million | $-38.51 Million | 0.691x | -44.11% |
| 2019-12-31 | $-41.42 Million | $-51.18 Million | 1.236x | +118.08% |
| 2018-12-31 | $4.25 Million | $-29.07 Million | -6.836x | -938.53% |
| 2017-12-31 | $-36.51 Million | $-29.77 Million | 0.815x | -85.20% |
| 2016-12-31 | $-5.34 Million | $-29.39 Million | 5.508x | +1014.04% |
| 2015-12-31 | $33.11 Million | $-19.95 Million | -0.603x | +18.41% |
| 2014-12-31 | $46.66 Million | $-34.46 Million | -0.739x | -10994.20% |
| 2013-12-31 | $73.16 Million | $-487.00K | -0.007x | +99.08% |
| 2012-12-31 | $33.85 Million | $-24.58 Million | -0.726x | +17.01% |
| 2011-12-31 | $17.47 Million | $-15.29 Million | -0.875x | -571.70% |
| 2010-12-31 | $-65.89 Million | $-12.22 Million | 0.186x | -49.37% |
| 2009-12-31 | $-52.99 Million | $-19.42 Million | 0.366x | -35.38% |
| 2008-12-31 | $-33.34 Million | $-18.90 Million | 0.567x | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more